Publications by authors named "Bao-cai Xing"
Objective: To explore the value of preoperative CT-based morphological heterogeneity (MH) for predicting local tumor disease-free survival (LTDFS) and progression-free survival (PFS) in patients with colorectal cancer liver metastases (CRLM).
Methods: The latest CT data of 102 CRLM patients were retrospectively analyzed. The morphological score of each liver metastasis was obtained, and the morphological heterogeneity difference (MHD) was calculated.
Introduction: Neoadjuvant chemotherapy is becoming routine for colorectal liver metastasis (CRLM) in patients with high risks of recurrence or in whom resection is difficult. This retrospective study aimed to establish a modified survival prediction model for patients with CRLM who underwent hepatectomy after neoadjuvant chemotherapy.
Materials And Methods: A total of 619 patients who received neoadjuvant chemotherapy followed by hepatectomy between 2006 and 2021 were included and divided into training and validation groups at a ratio of 2:1.
Article Synopsis
- The study examines the impact of RAS mutations on long-term survival in patients with colorectal liver metastases (CRLM) who have undergone hepatectomy.
- Researchers analyzed data from 399 CRLM patients, focusing on specific mutations in KRAS and NRAS genes, and used statistical methods to evaluate survival rates.
- The findings indicate that KRAS G12 mutations correlate with better survival outcomes, while KRAS Q61 and NRAS Q61 mutations are linked to worse survival, suggesting these mutations can help identify high-risk patients for targeted treatment strategies.
Article Synopsis
- A study was conducted to investigate how the baseline variant allele frequency (VAF) in circulating tumor DNA (ctDNA) affects prognosis in patients with colorectal cancer liver metastases (CRLM) post-surgery.
- * The research included 121 patients and found that a significant number of mutations in tumor tissues were also present in ctDNA, and lower VAF in ctDNA was linked to longer recurrence-free survival (RFS).
- * An integrated prognostic model that included baseline VAF and other factors was more accurate in predicting RFS compared to traditional models.
Article Synopsis
- Histopathological images of colorectal liver metastases (CRLM) contain valuable information that can help predict patient outcomes, but there hasn't been a deep learning framework focused on this area until now.
- The study developed a deep learning system that automates the classification and quantification of important spatial features in H&E-stained images of CRLM, showing robust prognostic value beyond current clinical risk scores.
- This automated framework could reduce the subjectivity and workload for pathologists, providing a cost-effective tool to improve clinical decision-making for CRLM patients.
Article Synopsis
- The study investigates survival outcomes in colorectal liver metastases (CRLM) patients having surgery with R1 margins (less than 1 mm), specifically looking at differences between parenchymal and vascular R1 margins.
- Among 283 patients analyzed, distinct survival rates were found: those with R0 resections had better survival compared to parenchymal R1, but no significant difference was observed between vascular R1 and other groups.
- The study concludes that parenchymal R1 represents a higher risk for poor outcomes, while vascular R1 has survival rates comparable to R0, suggesting that preoperative chemotherapy might help make more patients eligible for surgery.
Background: The recurrence rate after hepatic resection of colorectal liver metastases (CRLM) remains high. This study aimed to investigate postoperative circulating tumor DNA (ctDNA) based on ultra-deep next-generation sequencing (NGS) to predict patient recurrence and survival.
Methods: Using the high-throughput NGS method tagged with a dual-indexed unique molecular identifier, named the CRLM-specific 25-gene panel (J25), this study sequenced ctDNA in peripheral blood samples collected from 134 CRLM patients who underwent hepatectomy after postoperative day 6.
Background: Vessels that encapsulate tumor clusters (VETC) is a newly discovered vascular pattern in hepatocellular carcinoma (HCC), representing high biological aggressiveness. However, it remains unclear whether the prognostic impact of VETC differs in patients with different staged HCC. This study aimed to evaluate the effect of VETC on the prognosis of patients with HCC at different stages after hepatectomy.
View Article and Find Full Text PDFArticle Synopsis
- * A study analyzed 433 patients who had surgery between 2000 and 2016, finding that about 26.1% had no recurrence at the 5-year mark, with certain factors like RAS status and preoperative CEA levels influencing long-term survival.
- * The researchers developed a model to predict long-term survival based on these factors, which can help clinicians make more informed treatment decisions for patients with CRLM.
Background: Patients with colorectal liver metastases (CRLM) combined with hepatic lymph node (HLN) metastases have a poor prognosis. In this study, we developed and validated a model using clinical and magnetic resonance imaging (MRI) parameters to predict HLN status before surgery.
Methods: A total of 104 CRLM patients undergoing hepatic lymphonodectomy with pathologically confirmed HLN status after preoperative chemotherapy were enrolled in this study.
Article Synopsis
- The study aimed to determine how the location of the primary tumor (PTL) affects the survival prognosis of patients with colorectal liver metastasis (CRLM), especially considering the tumor burden, measured with a tumor burden score (TBS).
- Analyzed data from 524 left-sided and 118 right-sided primary tumors revealed that patients with right-sided tumors had worse 5-year overall survival (OS) than those with left-sided tumors, but this difference diminished when considering other prognostic factors.
- The results indicated that the impact of PTL on survival is more pronounced in patients with lower TBS, while for those with high tumor burden (TBS ≥7), the association between PTL and OS was not significant.
Article Synopsis
- The study investigates how the age of onset affects long-term outcomes in patients with colorectal cancer liver metastasis (CRLM), as early-onset cases are on the rise.
- Researchers analyzed a group of 1189 patients who underwent liver resection, categorizing them into early-onset (≤45 years), intermediate-onset (46-70 years), and late-onset (>70 years) groups.
- Results showed that early-onset patients had worse overall survival rates and were more likely to develop additional metastases, while RAS mutations negatively impacted survival in younger and middle-aged patients but not in older patients.
Background: Neoadjuvant chemotherapy (NC) improves the survival outcomes of selected patients with colorectal liver metastasis (CRLM). The benefits of irinotecan-based regimens in these patients are still under debate.
Aim: To compare the benefits of irinotecan- and oxaliplatin-based regimens in patients with resectable CRLM.
Background: The use of neoadjuvant chemotherapy (NAC) in resectable colorectal liver metastases (CRLM) patients is controversial. High-risk patients are more likely to benefit from NAC despite its hepatotoxic effects. Since patients with a high tumor burden receive NAC more frequently, previous retrospective studies have imbalanced baseline characteristics.
View Article and Find Full Text PDFThe aim was to identify the optimal criteria of postoperative complications (POCs) for predicting oncological outcomes after hepatectomy for colorectal liver metastases (CRLMs) and to investigate the variable prognostic implications of POCs according to the modified clinical score (M-CS). We identified 751 patients who underwent curative hepatic resection for CRLM between 2007 and 2018. Patients were categorized based on the M-CS.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how the number of liver metastases affects the overall survival of colorectal liver metastases (CRLM) patients following curative resection, with a specific focus on identifying different prognostic factors for varying numbers of liver metastases.
- A total of 1095 patients were categorized into three groups based on the number of liver metastases, revealing that a higher number of metastases is associated with lower survival rates, while RAS mutation consistently emerged as a key risk factor across all subgroups.
- Nomograms were developed to predict patient survival based on these identified prognostic factors, showing adequate performance in estimating overall survival across the different groups.
Article Synopsis
- Colorectal cancer liver metastasis (CRLM) significantly impacts the survival of patients with colorectal cancer (CRC), leading to the development of a new prognostic tool called the Circulating Lipid- and Inflammation-based Risk (CLIR) score for those undergoing CRLM resection.
- In a study of 666 CRC patients, key factors affecting overall survival (OS) were identified, including the number and size of metastases, lymph node involvement, and specific serum biomarker levels.
- The CLIR score was found to be more effective than the existing Fong Clinical Risk Score in predicting patient survival, with different risk categories showing median OS times ranging from 134 months for low-risk to 18.7 months for high
Background: The prognosis of patients with liver metastases during or early after adjuvant chemotherapy for colorectal cancer (CRC) is significantly worse. This study aimed to explore the efficacy of perioperative second-line chemotherapy in prolonging survival in those patients.
Methods: Patients who underwent liver resection, with resectable liver metastases that occurred within 12 months after the last cycle of adjuvant chemotherapy for CRC, from January 2006 to December 2019, were included.
Article Synopsis
- * Results showed that patients with left-sided tumors (LST) had better 5-year overall survival rates (47.1%) compared to those with right-sided tumors (RST) (31.0%), and those with wild-type RAS (RASwt) had superior survival rates (53.6%) compared to those with mutant RAS (RASmut) (24.0%).
- * The study demonstrated significant differences in both overall survival (OS) and disease-free survival (DFS) rates
Background: It is assumed that the impact of primary tumor stage (PTS) on prognosis gradually weakens with increasing disease-free interval (DFI) from colorectal cancer resection to liver metastases.
Methods: Data from 733 patients undergoing hepatectomy in the Hepato-pancreato-biliary Surgery Department I of Peking University Cancer Hospital were retrospectively analyzed. Early and late metastases were defined as DFI ≤ and >12 months, respectively.
Article Synopsis
- RECIST criteria, commonly used to evaluate treatment effectiveness in colorectal liver metastases (CRLM), have shown limitations in accuracy, prompting this study to compare them with functional MRI results.
- The study involved 137 CRLM patients undergoing neoadjuvant chemotherapy, divided into groups based on whether they received bevacizumab, measuring apparent diffusion coefficient (ADC) values to gauge overall and relapse-free survival.
- Findings indicated that post-treatment ADC values were significantly tied to better overall survival and relapse-free survival in the bevacizumab group, highlighting the superior predictive capability of ADC measurements over RECIST criteria.
Background: Preoperative chemotherapy has widely been used in colorectal cancer liver metastasis (CRLM). Pathological response to chemotherapy is very important in evaluating tumor biology. However, there is still a lack of a non-invasive and accurate method to evaluate pathological response before surgery.
View Article and Find Full Text PDFArticle Synopsis
- A clinical trial assessed the effectiveness and safety of I-labeled metuximab in combination with transcatheter arterial chemoembolization (TACE) for treating patients with unresectable hepatocellular carcinoma.
- Results showed that patients receiving TACE along with I-metuximab experienced a median time to tumor recurrence of 6 months compared to 3 months for those receiving TACE alone.
- Additionally, the combined treatment led to a median overall survival of 28 months versus 19 months for TACE alone, demonstrating better outcomes and good patient tolerance for the new treatment.
Background: Local treatment remains the best option for recurrent colorectal liver metastasis (CRLM). The current study aimed to investigate predictive factors of survival outcomes and select candidates for local treatment for CRLM at first recurrence.
Methods: Data were collected retrospectively from CRLM patients who underwent hepatic resection and developed first recurrence between 2000 and 2019 at our institution.